Overview
Study Investigating the Pharmacokinetic Properties of the Drug Lu AF35700 in Subjects With Liver Impairment and in Healthy Subjects
Status:
Completed
Completed
Trial end date:
2018-04-23
2018-04-23
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of this study is to assess the impact of mild to moderate hepatic impairment on the pharmacokinetics of a single oral dose of Lu AF35700Phase:
Phase 1Accepts Healthy Volunteers?
Accepts Healthy VolunteersDetails
Lead Sponsor:
H. Lundbeck A/S
Criteria
Inclusion Criteria:- Subjects with hepatic impairment disease stage Child-Pugh's Criteria A (mild) or
Child-Pugh's Criteria B (moderate) and healthy subjects with normal hepatic function
- Subjects have a body mass index between 18.5 and 34 kg/m2 (inclusive)
Exclusion Criteria:
- Subjects previously been dosed with Lu AF35700
Other protocol defined inclusion and exclusion criteria may apply